Co-Authors
This is a "connection" page, showing publications co-authored by RACHNA SHROFF and PRAJNAN DAS.
Connection Strength
0.338
-
Computed Tomography-Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer. JCO Precis Oncol. 2019; 3.
Score: 0.043
-
Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma. Cancer Med. 2018 10; 7(10):4880-4892.
Score: 0.040
-
A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2018 12 01; 24(23):5883-5894.
Score: 0.040
-
Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2017 Nov 01; 152(11):1048-1056.
Score: 0.038
-
Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater. Ann Surg Oncol. 2017 Jul; 24(7):2031-2039.
Score: 0.036
-
Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. J Gastrointest Surg. 2017 01; 21(1):164-174.
Score: 0.036
-
Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality. J Gastrointest Surg. 2016 12; 20(12):1975-1985.
Score: 0.036
-
Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Cancer. 2016 09 01; 122(17):2671-9.
Score: 0.035
-
Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis. J Clin Oncol. 2016 Jan 20; 34(3):219-26.
Score: 0.033